Who are Placebo in combination with Pembrolizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-in-combination-with-pembrolizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo in combination with Pembrolizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo in combination with Pembrolizumab (Placebo in combination with Pembrolizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor (Pembrolizumab component); Placebo control. Area: Oncology.

phase 3 PD-1 inhibitor (Pembrolizumab component); Placebo control PD-1 (Pembrolizumab component) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo in combination with Pembrolizumab (Placebo in combination with Pembrolizumab) — Akeso. Placebo serves as a control comparator in a combination study with Pembrolizumab, a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo in combination with Pembrolizumab TARGET	Placebo in combination with Pembrolizumab	Akeso	phase 3	PD-1 inhibitor (Pembrolizumab component); Placebo control	PD-1 (Pembrolizumab component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor (Pembrolizumab component); Placebo control class)

Akeso · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo in combination with Pembrolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-in-combination-with-pembrolizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab